Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ronald Mitsuyasu

Showing results (21-30 of 49) with videos related to

Pageof 5
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2015
Predictive Value of Cytokines and Immune Activation Biomarkers in AIDS-Related Non-Hodgkin Lymphoma Treated with Rituximab plus Infusional EPOCH (AMC-034 trial)Marta Epeldegui, Jeannette Y Lee, Anna C Martínez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 19, 2019
Pilot Trial AMC-063: Safety and Efficacy of Bortezomib in AIDS-associated Kaposi SarcomaErin G Reid, Adrienne Suazo, Shelly Y Lensing, et al.
Plos One|January 31, 2019
Re-boost immunizations with the peptide-based therapeutic HIV vaccine, Vacc-4x, restores geometric mean viral load set-point during treatment interruptionJürgen K Rockstroh, David Asmuth, Giuseppe Pantaleo, et al.
AIDS (London, England)|February 26, 2013
Immunosenescence is associated with presence of Kaposi's sarcoma in antiretroviral treated HIV infectionPatrick Unemori, Kieron S Leslie, Peter W Hunt, et al.
Blood Advances|December 22, 2018
Safety and efficacy of an oncolytic viral strategy using bortezomib with ICE/R in relapsed/refractory HIV-positive lymphomasErin G Reid, David Looney, Frank Maldarelli, et al.
Haematologica|February 29, 2020
Response-adapted therapy with infusional EPOCH chemotherapy plus rituximab in HIV-associated, B-cell non-Hodgkin's lymphomaJoseph A Sparano, Jeannette Y Lee, Lawrence D Kaplan, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 11, 2018
Safety and Preliminary Efficacy of Vorinostat With R-EPOCH in High-risk HIV-associated Non-Hodgkin's Lymphoma (AMC-075)Juan C Ramos, Joseph A Sparano, Michelle A Rudek, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 22, 2012
Pegylated liposomal doxorubicin, rituximab, cyclophosphamide, vincristine, and prednisone in AIDS-related lymphoma: AIDS Malignancy Consortium Study 047Alexandra M Levine, Ariela Noy, Jeannette Y Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 5, 2022
AMC-070: Lenalidomide Is Safe and Effective in HIV-Associated Kaposi SarcomaErin G Reid, Kelly Shimabukuro, Page Moore, et al.
Leukemia & Lymphoma|May 31, 2012
Outcome of patients with relapsed/refractory acquired immune deficiency syndrome-related lymphoma diagnosed 1999-2008 and treated with curative intent in the AIDS Malignancy ConsortiumUlas D Bayraktar, Juan Carlos Ramos, Adam Petrich, et al.
Pageof 5

Showing results (21-30 of 49) with videos related to

Sort By:
Pageof 5
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2015
Predictive Value of Cytokines and Immune Activation Biomarkers in AIDS-Related Non-Hodgkin Lymphoma Treated with Rituximab plus Infusional EPOCH (AMC-034 trial)Marta Epeldegui, Jeannette Y Lee, Anna C Martínez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 19, 2019
Pilot Trial AMC-063: Safety and Efficacy of Bortezomib in AIDS-associated Kaposi SarcomaErin G Reid, Adrienne Suazo, Shelly Y Lensing, et al.
Plos One|January 31, 2019
Re-boost immunizations with the peptide-based therapeutic HIV vaccine, Vacc-4x, restores geometric mean viral load set-point during treatment interruptionJürgen K Rockstroh, David Asmuth, Giuseppe Pantaleo, et al.
AIDS (London, England)|February 26, 2013
Immunosenescence is associated with presence of Kaposi's sarcoma in antiretroviral treated HIV infectionPatrick Unemori, Kieron S Leslie, Peter W Hunt, et al.
Blood Advances|December 22, 2018
Safety and efficacy of an oncolytic viral strategy using bortezomib with ICE/R in relapsed/refractory HIV-positive lymphomasErin G Reid, David Looney, Frank Maldarelli, et al.
Haematologica|February 29, 2020
Response-adapted therapy with infusional EPOCH chemotherapy plus rituximab in HIV-associated, B-cell non-Hodgkin's lymphomaJoseph A Sparano, Jeannette Y Lee, Lawrence D Kaplan, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 11, 2018
Safety and Preliminary Efficacy of Vorinostat With R-EPOCH in High-risk HIV-associated Non-Hodgkin's Lymphoma (AMC-075)Juan C Ramos, Joseph A Sparano, Michelle A Rudek, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 22, 2012
Pegylated liposomal doxorubicin, rituximab, cyclophosphamide, vincristine, and prednisone in AIDS-related lymphoma: AIDS Malignancy Consortium Study 047Alexandra M Levine, Ariela Noy, Jeannette Y Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 5, 2022
AMC-070: Lenalidomide Is Safe and Effective in HIV-Associated Kaposi SarcomaErin G Reid, Kelly Shimabukuro, Page Moore, et al.
Leukemia & Lymphoma|May 31, 2012
Outcome of patients with relapsed/refractory acquired immune deficiency syndrome-related lymphoma diagnosed 1999-2008 and treated with curative intent in the AIDS Malignancy ConsortiumUlas D Bayraktar, Juan Carlos Ramos, Adam Petrich, et al.
Pageof 5